股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司*（於開曼群島註冊成立的有限公司）*僅供識別 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 6,000,000,000 | USD | 0.000008333333 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 6,000,000,000 | U ...

Summary of Key Points Core Viewpoint - As of September 4, 60 stocks reached their 52-week highs, indicating a positive market trend with notable performances from specific companies such as Gaoshan Enterprises, Milan Station, and Yongyi International [1]. Group 1: 52-Week Highs - Gaoshan Enterprises (00616) achieved a closing price of 0.350 with a peak of 0.370, marking a high rate of 60.87% [1]. - Milan Station (01150) closed at 0.340, reaching a high of 0.360, with a high rate of 44.00% [1]. - Yongyi International (01218) had a closing price of 3.830 and a peak of 4.100, resulting in a high rate of 17.14% [1]. - Other notable stocks include: - Cheng Tian Jia He (01132) with a high rate of 16.49% [1]. - San Ye Cao Biotechnology - B (02197) with a high rate of 16.46% [1]. - Capital Financial Holdings (08239) with a high rate of 16.28% [1]. Group 2: 52-Week Lows - Wanma Holdings (02935) reached a low of 0.034, reflecting a decline of 25.00% [2]. - Rongyang Industrial (02078) had a closing price of 0.160, with a low of 0.069, indicating a drop of 15.85% [2]. - Energy International Investment (00353) closed at 0.295, reaching a low of 0.275, down by 12.70% [2]. - Other significant declines include: - Qianli Holdings (08367) with a drop of 12.00% [2]. - Yunkang Group (02325) with a decline of 10.71% [2]. - Wanwei International (00167) down by 7.41% [2].

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) experienced a decline of 3.38% on September 4, with a trading volume of 1.427 billion yuan. The fund has shown significant growth in both share volume and total assets since its inception in January 2024 [1][2]. Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159567) was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1]. - As of September 3, 2024, the fund's latest share volume was 6.668 billion shares, and its total assets reached 6.724 billion yuan. This represents an increase of 1586.48% in share volume and 1679.83% in total assets compared to December 31, 2023, when the share volume was 395 million shares and total assets were 378 million yuan [1]. Group 2: Trading Activity - Over the past 20 trading days, the cumulative trading amount for the Hong Kong Innovative Drug ETF (159567) was 33.138 billion yuan, with an average daily trading amount of 1.657 billion yuan. Since the beginning of the year, the cumulative trading amount over 165 trading days was 185.061 billion yuan, averaging 1.122 billion yuan per day [1]. Group 3: Fund Holdings - The current fund manager of the Hong Kong Innovative Drug ETF (159567) is Ma Jun, who has managed the fund since its inception, achieving a return of 99.52% during this period [2]. - Key holdings in the fund include: - Innovent Biologics (9.52% holding, 2.60 billion yuan market value) - WuXi Biologics (9.47% holding, 2.58 billion yuan market value) - BeiGene (8.73% holding, 2.38 billion yuan market value) - CanSino Biologics (7.62% holding, 2.08 billion yuan market value) - China National Pharmaceutical Group (7.17% holding, 1.96 billion yuan market value) - CSPC Pharmaceutical Group (6.34% holding, 1.73 billion yuan market value) - 3SBio (5.83% holding, 1.59 billion yuan market value) - Hansoh Pharmaceutical (4.54% holding, 1.24 billion yuan market value) - Zai Lab (2.86% holding, 781.055 million yuan market value) [2].

Core Insights - WuXi Biologics reported a 16.1% year-on-year revenue growth in the first half of 2025, reaching 9.95 billion yuan, with net profit attributable to shareholders increasing by 56.1% to 2.34 billion yuan [1] - Adjusted net profit grew by 6.2% year-on-year to 2.39 billion yuan, aligning with expectations, while the overall gross margin improved by 3.7 percentage points to 42.7% [1] Revenue Breakdown - IND pre-service revenue surged by 35.2% year-on-year to 4.15 billion yuan in the first half of 2025 [2] - Early-stage project revenue declined by 29.7% due to large projects transitioning to later development stages, while Phase III and commercial project revenue increased by 24.9% [2] - Revenue from the U.S. grew by 20.1%, accounting for 60.5% of total revenue, while Europe and China saw revenue growth of 5.7% and a decline of 8.5%, respectively [2] Project Pipeline - The company added 86 new projects in the first half of 2025, with over half coming from the U.S. and an improved contribution from China [3] - The total project count reached 864, including 67 Phase III projects and 24 commercial projects, indicating potential for future revenue growth [3] - Adjusted net profit forecasts for 2025 and 2026 were revised down to 4.90 billion yuan and 5.50 billion yuan, respectively, with a new forecast for 2027 set at 6.34 billion yuan [3]

Core Viewpoint - WuXi AppTec (02268.HK) announced a share placement at HKD 58.85 per share, aiming to raise approximately HKD 13.11 billion, with 90% of the proceeds intended for expanding service capacity and production [1][2] Group 1: Share Placement Details - The share placement involves a maximum of 22.28 million shares, with a discount of about 4.00% compared to the last trading day's closing price of HKD 61.3 per share, but a premium of approximately 2.87% over the average closing price of the previous five trading days [1][2] - The controlling shareholder, WuXi Biologics (02269.HK), subscribed to 24.134 million shares, amounting to approximately HKD 14.20 billion [1] Group 2: Company Performance and Market Position - WuXi AppTec's stock price has doubled since the first trading day of the year, reaching a historical high of HKD 61.3 per share [2][3] - The company reported revenue and net profit of CNY 2.701 billion and CNY 746 million for the first half of the year, representing year-on-year growth of 62.2% and 52.7%, respectively, driven by the active bioconjugate drug market [3] - The company has a backlog of unfulfilled orders amounting to USD 1.329 billion, a year-on-year increase of 57.9% [3] Group 3: Industry Outlook - The global ADC (Antibody-Drug Conjugate) market is projected to grow at a compound annual growth rate (CAGR) of 34% from 2020 to 2024 and 31% from 2024 to 2030, potentially reaching USD 66.2 billion by 2032 [5] - The outsourcing rate for ADC production is expected to be around 60%, significantly higher than the 34% for biopharmaceuticals, indicating a strong demand for WuXi AppTec's services [5]

Core Viewpoint - WuXi AppTec (02268) has announced a share placement agreement to raise approximately HKD 1.3 billion, primarily aimed at expanding its service capacity and production capabilities in bioconjugates and active pharmaceutical ingredients [1] Group 1: Share Placement Details - The company has signed a placement agreement with underwriters to fully underwrite up to 22.77 million shares at a price of HKD 58.85 per share, expecting net proceeds of about HKD 1.3 billion [1] - Approximately 90% of the raised funds will be allocated to enhance the group's service capacity and production capabilities, particularly in bioconjugates, active pharmaceutical ingredients, and clinical and commercial production [1] - The remaining 10% of the funds will be used for working capital and general corporate purposes [1] Group 2: Subscription Agreement - WuXi AppTec has also entered into a subscription agreement with its controlling shareholder, WuXi Biologics (02269), to issue 24.134 million subscription shares at the same price of HKD 58.85 per share, with net proceeds expected to be around HKD 1.4 billion [1] - Similar to the placement, about 90% of the subscription proceeds will be directed towards further expanding the group's service capacity and production capabilities, including bioconjugates and active pharmaceutical ingredients [1] - The remaining 10% will be allocated for the group's working capital needs and general corporate purposes [1]

Core Viewpoint - WuXi AppTec (02268) has announced a share placement agreement to raise approximately HKD 1.3 billion, primarily aimed at expanding its service capacity and production capabilities in bioconjugates and APIs [1] Group 1: Share Placement Details - The company signed a placement agreement to fully underwrite up to 22.77 million shares at a price of HKD 58.85 per share [1] - The expected net proceeds from this placement are approximately HKD 1.3 billion, with about 90% allocated for expanding service capacity and production, particularly in bioconjugates, APIs, and commercial production [1] - The remaining 10% of the funds will be used for working capital and general corporate purposes [1] Group 2: Subscription Agreement - WuXi AppTec has also entered into a subscription agreement with its controlling shareholder, WuXi Biologics (02269), to issue 24.134 million subscription shares at the same price of HKD 58.85 per share [1] - The net proceeds from this subscription are expected to be around HKD 1.4 billion, with a similar allocation of approximately 90% for expanding service capacity and production [1] - The remaining 10% will also be directed towards working capital needs and general corporate purposes [1]

Core Viewpoint - WuXi AppTec (02268.HK) has entered into a subscription agreement with WuXi Biologics (02269.HK) to issue and allocate 24.134 million shares at a subscription price of HKD 58.85 per share, raising approximately HKD 14.20 billion [1] Group 1 - The subscription price of HKD 58.85 represents a discount of about 4.00% compared to the last closing price of HKD 61.30 [1] - The total expected proceeds from the subscription are approximately HKD 14.20 billion, equivalent to about USD 1.82 billion [1] - The net proceeds from the subscription are expected to be around HKD 14.14 billion, or approximately USD 1.81 billion, with a net price per share of about HKD 58.61 [1] Group 2 - Approximately 90% of the net proceeds will be used to further expand the group's service capabilities and production capacity, including but not limited to clinical and commercial production capacity for antibody-drug conjugates, active pharmaceutical ingredients, and drugs [1] - About 10% of the net proceeds will be allocated for the group's working capital needs and general corporate purposes [1]

Core Viewpoint - WuXi AppTec (02268) has entered into a subscription agreement with its controlling shareholder WuXi Biologics (02269) to issue 24.134 million subscription shares at a price of HKD 58.85 per share, raising approximately HKD 1.42 billion [1] Group 1 - The net proceeds from the subscription are approximately HKD 1.414 billion [1] - About 90% of the proceeds will be used to further expand the group's service capabilities and production capacity, including but not limited to clinical and commercial production capacity for bioconjugated drugs, active pharmaceutical ingredients, and pharmaceuticals [1] - Approximately 10% of the proceeds will be allocated for the group's working capital needs and general corporate purposes [1] Group 2 - The subscriber is the controlling shareholder of the company, thus classified as a related party under the listing rules [1]

Core Viewpoint - WuXi AppTec (02268) announced a subscription agreement with WuXi Biologics (02269) to issue 24.134 million subscription shares at a price of HKD 58.85 per share, totaling approximately HKD 1.42 billion [1] Group 1 - The net proceeds from the subscription are approximately HKD 1.414 billion, with about 90% allocated for expanding the group's service capabilities and production capacity, including clinical and commercial production of bioconjugates, active pharmaceutical ingredients, and drugs [1] - Approximately 10% of the proceeds will be used for the group's working capital needs and general corporate purposes [1] - The subscriber is the controlling shareholder of the company, qualifying as a related party under the listing rules [1]